References
- Falay O, Öztürk E, Bölükbaşı Y, et al. Use of flurodeoxyglucose positron emission tomography for diagnosis of bleomycin-induced pneumonitis in Hodgkin Lymphoma. Leuk Lymphoma. 2017;58:1114–1122.
- Sleijfer S. Bleomycin-induced pneumonitis. Chest. 2001;120:617–624.
- Martin WG, Ristow KM, Habermann TM, et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. J Clin Oncol. 2005;23:7614–7620.
- Böll B, Goergen H, Behringer K, et al. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood. 2016;127:2189–2192.
- Macann A, Bredenfeld H, Muller RP, et al. Radiotherapy does not influence the severe pulmonary toxicity observed with the administration of gemcitabine and bleomycin in patients with advanced-stage Hodgkin’s lymphoma treated with the BAGCOPP regimen: a report by the German Hodgkin’s Lymphoma Study Group. Int J Radiat Oncol Biol Phys. 2008;70:161–165.
- Younes A, Connors JM, Park SI, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013;14:1348–1356.
- Bellamy EA, Husband JE, Blaquiere RM, et al. Bleomycin-related lung damage: CT evidence. Radiology. 1985;156:155–158.
- Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT Scan in advanced Hodgkin’s Lymphoma. N Engl J Med. 2016;374:2419–2429.
- Haverkamp H, Böll B, Eichenauer DA, et al. Impact of bleomycin and vincristine dose reductions in patients with advanced hodgkin lymphoma treated With BEACOPP: an analysis of the german hodgkin study group HD12 and HD15 Trials. J Clin Oncol. 2015;33:2430–2436.